Azacytidine and Valproic Acid in Patients With Advanced Cancers
Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
1. To evaluate side effects and maximum tolerated dose of azacitidine and valproic acid in
patients with advanced cancer.
Secondary Objectives:
1. To perform a preliminary assessment of the histone acetylation and DNA methylation
effects of this combination on peripheral blood mononuclear cells (PBMC).
2. To assess the clinical anti-tumor activity (objective response including complete and
partial responses) of this combination in patients with advanced cancer, in a
descriptive fashion.